13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595855
Total reported value
$1.1B
$1.1B
51 檔
17.9%
According to the latest 13F quarterly dataset, Opaleye Management Inc. managed an equity portfolio of $1.1B at the end of Q2 2024, spanning 51 distinct U.S. exchange-listed positions.
During Q2 2024, Opaleye Management Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HROW | Harrow Inc | Stock-Other | 19.04% | -3.92% | +1.77% | |
| 2 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 9.27% | +0.32% | — | |
| 3 | OCUL | Ocular Therapeutix Inc | Stock-Other | 8.29% | -0.14% | -20.23% | |
| 4 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.83% | -3.42% | — | |
| 5 | KROS | Keros Therapeutics Inc | Stock-Other | 3.84% | — | — | |
| 6 | ARVN | Arvinas Inc | Stock-Other | 3.38% | — | +68.18% | |
| 7 | IMNM | Immunome Inc | Stock-Other | 3.05% | — | — | |
| 8 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.46% | — | — | |
| 9 | CDXS | Codexis Inc | Stock-Other | 2.45% | -0.07% | +10.74% | |
| 10 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.39% | -0.23% | -12.78% | |
| 11 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 2.27% | — | -36.28% | |
| 12 | CRGX | Cargo Therapeutics Inc | Stock-Other | 2.08% | — | — | |
| 13 | JSPR | Jasper Therapeutics Inc | Stock-Other | 2.03% | — | -10.00% | |
| 14 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.00% | — | +56.78% | |
| 15 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.80% | -0.02% | — | |
| 16 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 1.80% | +0.08% | -2.08% | |
| 17 | APLT | Applied Therapeutics Inc | Stock-Other | 1.79% | — | -5.08% | |
| 18 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.66% | +0.26% | +0.47% | |
| 19 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 1.64% | — | — | |
| 20 | ✓ | Acelyrin Inc | Stock-Other | 1.59% | — | — | |
| 21 | URGN | UroGen Pharma Ltd. | Stock-Other | 1.58% | +1.41% | +52.59% | |
| 22 | PCVX | Vaxcyte Inc | Stock-Other | 1.47% | — | — | |
| 23 | ✓ | Biodesix Inc | Stock-Other | 1.41% | — | +651.88% | |
| 24 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.38% | — | -0.12% | |
| 25 | XOMA | Xoma Royalty Corporation | Stock-Other | 1.35% | +0.06% | — | |
| 26 | TARA | Protara Therapeutic Inc | Stock-Other | 1.21% | — | -14.42% | |
| 27 | NTLA | Intellia Therapeutics Inc | Stock-Other | 1.11% | -0.03% | -14.51% | |
| 28 | NUVL | Nuvalent Inc-a | Stock-Other | 1.03% | — | — | |
| 29 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 1.02% | — | +9.89% | |
| 30 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | Bond | 0.90% | — | — | |
| 31 | LQDA | Liquidia CORP | Stock-Other | 0.89% | +5.97% | -17.72% | |
| 32 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 0.86% | — | — | |
| 33 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.83% | -0.28% | -6.83% | |
| 34 | GOSS | Gossamer Bio Inc | Stock-Other | 0.80% | — | +60.24% | |
| 35 | LXRX | Lexicon Pharmaceuticals Inc | Stock-Other | 0.72% | — | — | |
| 36 | SVRA | Savara Inc | Stock-Other | 0.66% | — | -16.38% | |
| 37 | ALLKGUSD | Allakos Inc | Stock-Other | 0.64% | — | +14.17% | |
| 38 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.63% | — | -7.39% | |
| 39 | VSTM | Verastem Inc | Stock-Other | 0.62% | +0.62% | NEW | |
| 40 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.60% | — | +766.08% | |
| 41 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 0.55% | — | -50.22% | |
| 42 | RLMD | Relmada Therapeutics Inc | Stock-Other | 0.41% | -0.27% | -20.95% | |
| 43 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.40% | — | +119.23% | |
| 44 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.28% | — | — | |
| 45 | IBIO | Ibio Inc | Stock-Other | 0.18% | — | -44.85% | |
| 46 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 0.18% | — | +0.75% | |
| 47 | ✓ | Stock-Other | 0.17% | — | — | ||
| 48 | DSGN | Design Therapeutics Inc | Stock-Other | 0.16% | — | +81.35% | |
| 49 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.14% | — | — | |
| 50 | ✓ | Aligos Therapeutics Inc | Stock-Other | 0.10% | — | -22.70% |
According to official SEC Form 13F filings, Opaleye Management Inc. reported a total U.S. public equity portfolio value of $1.1B across 51 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HROW, TGTX, OCUL) accounted for 17.9% of total reported equity market value during Q2 2024.
During Q2 2024, Opaleye Management Inc.'s top holdings by market value included HROW (19.0%)、TGTX (9.3%)、OCUL (8.3%). The largest single position, HROW, represented 19.0% of total portfolio value.
In Q2 2024, Opaleye Management Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.